Search research articles
Contact Us
Filters
Showing results (51-60 of 77) with videos related to
Page
of 8
Sort By:
Rheumatology Advances in Practice
|
August 22, 2019
Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort: reply
Fariz Yahya, Karl Gaffney, Louise Hamilton, et al.
Rheumatology and Therapy
|
January 12, 2023
Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons
Nurullah Akkoç, Carlos H Arteaga, Simone E Auteri, et al.
Rheumatology Advances in Practice
|
August 15, 2020
Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study
Liz Van Rossen, Antoni Chan, Annie Gilbert, et al.
Rheumatology (Oxford, England)
|
December 23, 2017
Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort
Fariz Yahya, Karl Gaffney, Louise Hamilton, et al.
Rheumatology and Therapy
|
June 8, 2022
Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
Uta Kiltz, Petros P Sfikakis, Karl Gaffney, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
August 26, 2023
The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease
Ulf Müller-Ladner, Axel Dignass, Karl Gaffney, et al.
RMD Open
|
May 13, 2026
Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension
Victoria Navarro-Compán, Uta Kiltz, Philip J Mease, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
February 27, 2025
Delayed diagnosis of axial spondyloarthritis: the crucial role of primary care - how you can make a difference
Thomas A Ingram, Joe Eddison, Karl Gaffney, et al.
BMC Rheumatology
|
May 31, 2019
AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS)
Gary J Macfarlane, Ejaz Pathan, Stefan Siebert, et al.
Rheumatology (Oxford, England)
|
April 25, 2025
What is the economic burden of delayed axial spondyloarthritis diagnosis in the UK?
Fernando Zanghelini, George Xydopoulos, Stephanie Howard Wilsher, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 77) with videos related to
Sort By:
Page
of 8
Rheumatology Advances in Practice
|
August 22, 2019
Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort: reply
Fariz Yahya, Karl Gaffney, Louise Hamilton, et al.
Rheumatology and Therapy
|
January 12, 2023
Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons
Nurullah Akkoç, Carlos H Arteaga, Simone E Auteri, et al.
Rheumatology Advances in Practice
|
August 15, 2020
Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study
Liz Van Rossen, Antoni Chan, Annie Gilbert, et al.
Rheumatology (Oxford, England)
|
December 23, 2017
Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort
Fariz Yahya, Karl Gaffney, Louise Hamilton, et al.
Rheumatology and Therapy
|
June 8, 2022
Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
Uta Kiltz, Petros P Sfikakis, Karl Gaffney, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
August 26, 2023
The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease
Ulf Müller-Ladner, Axel Dignass, Karl Gaffney, et al.
RMD Open
|
May 13, 2026
Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension
Victoria Navarro-Compán, Uta Kiltz, Philip J Mease, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
February 27, 2025
Delayed diagnosis of axial spondyloarthritis: the crucial role of primary care - how you can make a difference
Thomas A Ingram, Joe Eddison, Karl Gaffney, et al.
BMC Rheumatology
|
May 31, 2019
AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS)
Gary J Macfarlane, Ejaz Pathan, Stefan Siebert, et al.
Rheumatology (Oxford, England)
|
April 25, 2025
What is the economic burden of delayed axial spondyloarthritis diagnosis in the UK?
Fernando Zanghelini, George Xydopoulos, Stephanie Howard Wilsher, et al.
Page
of 8